24th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2024)
| When | Tuesday, June 18, 2024 - Friday, June 21, 2024 |
| Where | San Francisco United States |
| Category | Immunology |
| Location | |
| Endorsed by |
| Share this page: |  |
 |
 |
 |
About the event
FOCIS is the meeting in translational immunology that will give you a competitive edge in your career. Stay ahead of the curve with leading clinicians and researchers delivering the latest breakthroughs across immune-mediated diseases. Focusing on molecular pathways and their implications in human disease provides the unique opportunity for innovative thinking and applying ideas from the pathologies of other diseases to uncover novel solutions to challenges in the diseases you study.
Through the FOCIS Annual Meeting, researchers and clinicians share knowledge across traditional disease borders and identify commonalities between treatments and therapies that are life-changing for those affected by immune-mediated diseases. From the introduction of monoclonal antibodies in clinical practice to recent advances in cancer immunotherapy, the past more than two decades have been transformational for patients living with immune-mediated diseases.
FOCIS is the meeting in translational immunology that will give you a competitive edge in your career. Stay ahead of the curve with leading clinicians and researchers delivering the latest breakthroughs across immune-mediated diseases. Focusing on molecular pathways and their implications in human disease provides the unique opportunity for innovative thinking and applying ideas from the pathologies of other diseases to uncover novel solutions to challenges in the diseases you study.
Through the FOCIS Annual Meeting, researchers and clinicians share knowledge across traditional disease borders and identify commonalities between treatments and therapies that are life-changing for those affected by immune-mediated diseases. From the introduction of monoclonal antibodies in clinical practice to recent advances in cancer immunotherapy, the past more than two decades have been transformational for patients living with immune-mediated diseases.